Paul Leger1, Sanika Chirwa, Megan Turner, Danielle M Richardson, Paxton Baker, Michael Leonard, Husamettin Erdem, Lana Olson, David W Haas. 1. aDepartment of Medicine bVanderbilt Technologies for Advanced Genomics Analysis and Research Design (VANGARD) cVanderbilt Technologies for Advanced Genomics (VANTAGE), Vanderbilt University Medical Center dDepartment of Medicine, Pharmacology, Pathology, Microbiology & Immunology, Vanderbilt University School of Medicine eDepartment of Neuroscience & Pharmacology, Meharry Medical College, Nashville, Tennessee, USA.
Abstract
BACKGROUND: Efavirenz frequently causes central nervous system (CNS) symptoms. We evaluated genetic associations with efavirenz discontinuation for CNS symptoms within 12 months of treatment initiation. METHODS: Patients had initiated efavirenz-containing regimens at an HIV primary care clinic in the Southeastern United States and had at least 12 months of follow-up data. Polymorphisms in CYP2B6 and CYP2A6 defined efavirenz metabolizer categories. Genome-wide genotyping enabled adjustment for population stratification. RESULTS: Among 563 evaluable patients, 99 (17.5%) discontinued efavirenz within 12 months, 29 (5.1%) for CNS symptoms. The hazard ratio (HR) for efavirenz discontinuation for CNS symptoms in slow versus extensive metabolizers was 4.9 [95% confidence interval (CI): 1.9-12.4; P=0.001]. This HR in Whites was 6.5 (95% CI: 2.3-18.8; P=0.001) and 2.6 in Blacks (95% CI: 0.5-14.1; P=0.27). Considering only slow metabolizers, the HR in Whites versus Blacks was 3.1 (95% CI: 0.9-11.0; P=0.081). The positive predictive value of slow metabolizer genotypes for efavirenz discontinuation was 27% in Whites and 11% in Blacks. CONCLUSION: Slow metabolizer genotypes were associated significantly with efavirenz discontinuation for reported CNS symptoms. This association was considerably stronger in Whites than in Blacks.
BACKGROUND:Efavirenz frequently causes central nervous system (CNS) symptoms. We evaluated genetic associations with efavirenz discontinuation for CNS symptoms within 12 months of treatment initiation. METHODS:Patients had initiated efavirenz-containing regimens at an HIV primary care clinic in the Southeastern United States and had at least 12 months of follow-up data. Polymorphisms in CYP2B6 and CYP2A6 defined efavirenz metabolizer categories. Genome-wide genotyping enabled adjustment for population stratification. RESULTS: Among 563 evaluable patients, 99 (17.5%) discontinued efavirenz within 12 months, 29 (5.1%) for CNS symptoms. The hazard ratio (HR) for efavirenz discontinuation for CNS symptoms in slow versus extensive metabolizers was 4.9 [95% confidence interval (CI): 1.9-12.4; P=0.001]. This HR in Whites was 6.5 (95% CI: 2.3-18.8; P=0.001) and 2.6 in Blacks (95% CI: 0.5-14.1; P=0.27). Considering only slow metabolizers, the HR in Whites versus Blacks was 3.1 (95% CI: 0.9-11.0; P=0.081). The positive predictive value of slow metabolizer genotypes for efavirenz discontinuation was 27% in Whites and 11% in Blacks. CONCLUSION: Slow metabolizer genotypes were associated significantly with efavirenz discontinuation for reported CNS symptoms. This association was considerably stronger in Whites than in Blacks.
Authors: Bryan A Ward; J Christopher Gorski; David R Jones; Stephen D Hall; David A Flockhart; Zeruesenay Desta Journal: J Pharmacol Exp Ther Date: 2003-04-03 Impact factor: 4.030
Authors: David W Haas; Laura M Smeaton; Robert W Shafer; Gregory K Robbins; Gene D Morse; Line Labbe; Grant R Wilkinson; David B Clifford; Richard T D'Aquila; Victor De Gruttola; Richard B Pollard; Thomas C Merigan; Martin S Hirsch; Alfred L George; John P Donahue; Richard B Kim Journal: J Infect Dis Date: 2005-11-01 Impact factor: 5.226
Authors: Heather J Ribaudo; Huan Liu; Matthias Schwab; Elke Schaeffeler; Michel Eichelbaum; Alison A Motsinger-Reif; Marylyn D Ritchie; Ulrich M Zanger; Edward P Acosta; Gene D Morse; Roy M Gulick; Gregory K Robbins; David Clifford; David W Haas Journal: J Infect Dis Date: 2010-09-01 Impact factor: 5.226
Authors: David W Haas; Awewura Kwara; Danielle M Richardson; Paxton Baker; Ioannis Papageorgiou; Edward P Acosta; Gene D Morse; Michael H Court Journal: J Antimicrob Chemother Date: 2014-04-11 Impact factor: 5.790
Authors: Bruce R Schackman; David W Haas; Sanghee S Park; X Cynthia Li; Kenneth A Freedberg Journal: Pharmacogenomics Date: 2015-11-26 Impact factor: 2.533
Authors: Nathan W Cummins; Jacqueline Neuhaus; Haitao Chu; James Neaton; Christoph Wyen; Jürgen K Rockstroh; Daniel J Skiest; Mark A Boyd; Saye Khoo; Margalida Rotger; Amalio Telenti; Richard Weinshilboum; Andrew D Badley Journal: EBioMedicine Date: 2015-05-12 Impact factor: 8.143
Authors: Tailah Bernardo de Almeida; Marcelo Costa Velho Mendes de Azevedo; Jorge Francisco da Cunha Pinto; Fernando Rafael de Almeida Ferry; Guilherme Almeida Rosa da Silva; Izana Junqueira de Castro; Paxton Baker; Amilcar Tanuri; David W Haas; Cynthia C Cardoso Journal: J Antimicrob Chemother Date: 2018-09-01 Impact factor: 5.790
Authors: David W Haas; Yuki Bradford; Anurag Verma; Shefali S Verma; Joseph J Eron; Roy M Gulick; Sharon A Riddler; Paul E Sax; Eric S Daar; Gene D Morse; Edward P Acosta; Marylyn D Ritchie Journal: Pharmacogenet Genomics Date: 2018-07 Impact factor: 2.089
Authors: Zeruesenay Desta; Roseann S Gammal; Li Gong; Michelle Whirl-Carrillo; Aditya H Gaur; Chonlaphat Sukasem; Jennifer Hockings; Alan Myers; Marelize Swart; Rachel F Tyndale; Collen Masimirembwa; Otito F Iwuchukwu; Sanika Chirwa; Jeffrey Lennox; Andrea Gaedigk; Teri E Klein; David W Haas Journal: Clin Pharmacol Ther Date: 2019-07-05 Impact factor: 6.875
Authors: David W Haas; Anthony T Podany; Yajing Bao; Susan Swindells; Richard E Chaisson; Noluthando Mwelase; Khuanchai Supparatpinyo; Lerato Mohapi; Amita Gupta; Constance A Benson; Paxton Baker; Courtney V Fletcher Journal: Pharmacogenet Genomics Date: 2021-01 Impact factor: 2.000
Authors: Michael A Leonard; Zinhle Cindi; Yuki Bradford; Kassem Bourgi; John Koethe; Megan Turner; Jamison Norwood; Beverly Woodward; Husamettin Erdem; Rebecca Basham; Paxton Baker; Peter F Rebeiro; Timothy R Sterling; Todd Hulgan; Eric S Daar; Roy Gulick; Sharon A Riddler; Phumla Sinxadi; Marylyn D Ritchie; David W Haas Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 20.999
Authors: Anurag Verma; Yuki Bradford; Shefali S Verma; Sarah A Pendergrass; Eric S Daar; Charles Venuto; Gene D Morse; Marylyn D Ritchie; David W Haas Journal: Pharmacogenet Genomics Date: 2017-03 Impact factor: 2.089
Authors: Katie R Mollan; Camlin Tierney; Jacklyn N Hellwege; Joseph J Eron; Michael G Hudgens; Roy M Gulick; Richard Haubrich; Paul E Sax; Thomas B Campbell; Eric S Daar; Kevin R Robertson; Diana Ventura; Qing Ma; Digna R Velez Edwards; David W Haas Journal: J Infect Dis Date: 2017-09-01 Impact factor: 5.226
Authors: Paul Leger; Sanika Chirwa; Jacinta N Nwogu; Megan Turner; Danielle M Richardson; Paxton Baker; Michael Leonard; Husamettin Erdem; Lana Olson; David W Haas Journal: Pharmacogenet Genomics Date: 2018-01 Impact factor: 2.089
Authors: Jacinta N Nwogu; Monica Gandhi; Andrew Owen; Saye H Khoo; Babafemi Taiwo; Adeniyi Olagunju; Baiba Berzins; Hideaki Okochi; Regina Tallerico; Kevin Robertson; Chinedum P Babalola Journal: AIDS Date: 2021-10-01 Impact factor: 4.632